An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer

J. Rubin, D. A. Decker, D. L. Ahmann, R. T. Eagan, J. N. Ingle, R. G. Hahn

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A phase II study utilizing VP-16 and adriamycin in a randomized fashion tested the concept of synchronization of the drugs in treatment of metastatic breast cancer. Although there was a trend in median survival following the synchronized schedule, there was no significant difference in survival or progression-free intervals. The concept of synchronization was not established.

Original languageEnglish (US)
Pages (from-to)149-151
Number of pages3
JournalOncology
Volume37
Issue number3
StatePublished - 1980
Externally publishedYes

Fingerprint

Etoposide
Doxorubicin
Disease-Free Survival
Appointments and Schedules
Breast Neoplasms
Survival
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rubin, J., Decker, D. A., Ahmann, D. L., Eagan, R. T., Ingle, J. N., & Hahn, R. G. (1980). An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer. Oncology, 37(3), 149-151.

An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer. / Rubin, J.; Decker, D. A.; Ahmann, D. L.; Eagan, R. T.; Ingle, J. N.; Hahn, R. G.

In: Oncology, Vol. 37, No. 3, 1980, p. 149-151.

Research output: Contribution to journalArticle

Rubin, J, Decker, DA, Ahmann, DL, Eagan, RT, Ingle, JN & Hahn, RG 1980, 'An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer', Oncology, vol. 37, no. 3, pp. 149-151.
Rubin J, Decker DA, Ahmann DL, Eagan RT, Ingle JN, Hahn RG. An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer. Oncology. 1980;37(3):149-151.
Rubin, J. ; Decker, D. A. ; Ahmann, D. L. ; Eagan, R. T. ; Ingle, J. N. ; Hahn, R. G. / An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer. In: Oncology. 1980 ; Vol. 37, No. 3. pp. 149-151.
@article{dbd75b720c434e15985c2bbd01dadd64,
title = "An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer",
abstract = "A phase II study utilizing VP-16 and adriamycin in a randomized fashion tested the concept of synchronization of the drugs in treatment of metastatic breast cancer. Although there was a trend in median survival following the synchronized schedule, there was no significant difference in survival or progression-free intervals. The concept of synchronization was not established.",
author = "J. Rubin and Decker, {D. A.} and Ahmann, {D. L.} and Eagan, {R. T.} and Ingle, {J. N.} and Hahn, {R. G.}",
year = "1980",
language = "English (US)",
volume = "37",
pages = "149--151",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer

AU - Rubin, J.

AU - Decker, D. A.

AU - Ahmann, D. L.

AU - Eagan, R. T.

AU - Ingle, J. N.

AU - Hahn, R. G.

PY - 1980

Y1 - 1980

N2 - A phase II study utilizing VP-16 and adriamycin in a randomized fashion tested the concept of synchronization of the drugs in treatment of metastatic breast cancer. Although there was a trend in median survival following the synchronized schedule, there was no significant difference in survival or progression-free intervals. The concept of synchronization was not established.

AB - A phase II study utilizing VP-16 and adriamycin in a randomized fashion tested the concept of synchronization of the drugs in treatment of metastatic breast cancer. Although there was a trend in median survival following the synchronized schedule, there was no significant difference in survival or progression-free intervals. The concept of synchronization was not established.

UR - http://www.scopus.com/inward/record.url?scp=0018844312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018844312&partnerID=8YFLogxK

M3 - Article

C2 - 7360486

AN - SCOPUS:0018844312

VL - 37

SP - 149

EP - 151

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -